新希望六和股份有限公司 章 程 1 目 录 第五章 董事会 第六章 高级管理人员 2 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东会 第一节 股东的一般规定 第二节 控股股东和实际控制人 第三节 股东会的一般规定 第四节 股东会的召集 第五节 股东会的提案与通知 第六节 股东会的召开 第七节 股东会的表决和决议 第一节 董事的一般规定 第二节 董事会 第三节 独立董事 第四节 董事会专门委员会 第七章 监事会 第二节 公告 3 第一节 监事的一般规定 第二节 监事会 第八章 财务会计制度、利润分配和审计 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第九章 通知与公告 第一节 通知 第十章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 第二节 解散和清算 第十一章 修改章程 第十二章 附则 第一章 总则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共 和国证券法》（以下简称《证券法》）和其他 ...

智通财经4月29日电，新希望(000876.SZ)发布2025年第一季度报告，实现营业收入244.17亿元，同比增 长2.13%；归属于上市公司股东的净利润为4446.88万元，同比扭亏。 新希望：一季度净利润4446.88万元 同比扭亏 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 24.42 billion, an increase of 2.13% compared to CNY 23.91 billion in the same period last year[5]. - Net profit attributable to shareholders was CNY 444.69 million, a significant increase of 122.99% from a loss of CNY 1.93 billion in the previous year[5]. - The net cash flow from operating activities reached CNY 966.67 million, representing a remarkable increase of 633.20% compared to CNY 131.84 million in the same period last year[5]. - Basic and diluted earnings per share improved to CNY 0.09, up 120.93% from a loss of CNY 0.43 per share in the previous year[5]. - The weighted average return on equity increased to 1.64%, up 10.27 percentage points from -8.63% in the same period last year[5]. - Total operating revenue for the current period reached ¥24,417,096,879.71, an increase from ¥23,908,453,072.71 in the previous period, reflecting a growth of approximately 2.12%[17]. - Net profit for the current period was ¥505,543,244.48, a significant recovery from a net loss of ¥2,360,959,435.11 in the previous period[18]. - The company reported an operating profit of ¥659,454,173.24, compared to an operating loss of ¥2,225,280,270.81 in the previous period[18]. - The total comprehensive income attributable to the parent company was CNY 224,910,225.75, compared to a loss of CNY 2,068,345,080.62 in the previous period[19]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 117.94 billion, a slight increase of 0.03% from CNY 117.91 billion at the end of the previous year[5]. - Total assets amounted to ¥117,943,565,394.65, slightly up from ¥117,913,645,385.32[16]. - Total liabilities increased to ¥81,674,860,181.71 from ¥81,368,210,423.30, indicating a rise of approximately 0.38%[16]. - The company's equity attributable to shareholders rose to ¥25,730,226,442.35 from ¥25,657,330,263.70, showing a growth of about 0.28%[16]. Cash Flow - The net cash flow from operating activities was CNY 966,674,184.89, an increase from CNY 131,843,313.43 in the previous period[20]. - Cash inflow from operating activities totaled CNY 24,625,416,447.86, down from CNY 25,008,289,843.02 in the previous period[20]. - The net cash flow from investing activities was -CNY 390,338,743.28, an improvement from -CNY 1,023,396,257.15 in the previous period[21]. - The net cash flow from financing activities was -CNY 636,501,819.41, compared to a positive cash flow of CNY 988,614,403.95 in the previous period[21]. - The total cash and cash equivalents at the end of the period were CNY 7,210,603,023.29, down from CNY 8,689,734,369.49 at the end of the previous period[21]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 221,296[10]. - The company has a significant shareholder structure, with the largest shareholder, Nanfang Hope Industry Co., Ltd., holding 1,328,957,185 shares, representing a substantial portion of the equity[11]. - The company has not reported any significant changes in its financing or securities lending activities among its top shareholders[11]. Management and Governance - The company has appointed Liu Chang as the chairman of the board for a term of three years, indicating a stable leadership structure moving forward[13]. - The board of directors has established several committees, including a strategic development committee, which will focus on long-term growth strategies[13]. - The company is preparing for its 2025 annual general meeting, which will include the election of new board members and committee members, ensuring governance continuity[12]. Market and Product Development - The company is actively engaging in market expansion and product development, although specific new products or technologies were not detailed in the call[12]. - The company plans to focus on market expansion and new product development in the upcoming quarters to sustain growth momentum[18].

证券研究报告 新希望 (000876 CH) 主业聚焦效果显现，资金面趋于稳健 | 华泰研究 | | | 年报点评 | | --- | --- | --- | --- | | 2025 年 | 4 月 | 28 日│中国内地 | 农业综合 | 新希望发布年报，2024 年实现营收 1030.63 亿元（yoy-27.27%），归母净 利 4.74 亿元（yoy+90.05%），扣非净利 6.14 亿元（yoy+113.33%）。其中 Q4 实现营收 258.54 亿元（yoy-26.04%，qoq-6.43%），归母净利 3.20 亿 元（yoy-92.20%，qoq-76.63%）。公司 2024 年聚焦主业，经营优化显著， 看好公司成本下降空间及资金面持续优化，维持"增持"评级。 业务聚焦效果显现，24 年归母净利润同比+90% 受 2023 年年底公司转让白羽肉禽和食品深加工板块的控股权影响，2024 年营收同比下滑，而在猪价上升、成本优化等的带动下公司养猪业务大幅减 亏，同时饲料业务核心竞争力突出、持续贡献稳定盈利，公司 2024 年经营 表现优于去年，归母净利润同比+90%。具体：1）饲料实现营收 ...

Core Viewpoint - Myopia among adolescents has become a global public health issue, with over 50% prevalence in China, necessitating new intervention methods beyond existing treatments like low-concentration atropine eye drops [1][2]. Group 1: Current Challenges in Myopia Prevention - Low-concentration atropine effectively delays myopia progression by approximately 60% but only controls axial length growth by about 30%, indicating a significant limitation [2]. - The dual effects of atropine include measurement bias due to its dilation effect and a compensatory response that may lead to pathological elongation of the eyeball [2]. Group 2: Discovery of Crocetin - A groundbreaking study from Japan identified Crocetin as a potent activator of EGR-1, a key transcription factor in regulating cell proliferation and differentiation, which may intervene in myopia progression [3]. - In a mouse model, Crocetin significantly reduced axial length growth compared to the control group [5]. Group 3: Clinical Trials and Efficacy - A clinical study involving 67 children aged 6-12 showed that daily oral administration of 7.5mg Crocetin for six months resulted in a significant increase in choroidal thickness compared to the control group [8][10]. - The increase in choroidal thickness is crucial as it improves retinal metabolic conditions and inhibits scleral hypoxic expansion [10]. Group 4: Mechanisms of Action - Crocetin's effects may be attributed to multiple pathways, including EGR-1 activation, antioxidant stress response, and improved choroidal blood flow [11][13]. - Both spherical equivalent refraction and axial length measurements showed significant improvement in the Crocetin group compared to controls [12]. Group 5: Advantages and Future Prospects - Crocetin offers several advantages over traditional drugs, including its natural origin, safety for long-term use, and multi-target action addressing both axial length and refractive error [14]. - Ongoing multi-center clinical trials in China aim to validate the efficacy of different doses of Crocetin for children, with potential complementary use alongside low-concentration atropine [14]. - The development of precise drug delivery systems, such as nano-sustained release eye drops, may position Crocetin as a key player in altering the course of myopia [15].

Core Insights - The article discusses the structure and dynamics of the feed industry in China, highlighting the upstream raw materials, midstream production, and downstream demand from farming and aquaculture sectors [1][4][6]. Industry Chain Overview - The feed industry chain consists of three segments: upstream raw materials (energy, protein, and microbial sources), midstream feed product development and production (including pig, poultry, ruminant, and aquaculture feeds), and downstream demand primarily from farmers and aquaculture enterprises [1]. - Recent government initiatives aim to reduce reliance on imported corn and soybean meal, leading to a gradual establishment of domestic raw material sources and improved stability [1]. - Midstream companies are enhancing innovation capabilities and accelerating new product development, with increasing vertical integration between midstream and upstream/downstream sectors [1]. - Rising meat consumption levels in China are expected to boost the scale of downstream aquaculture and livestock farming [1]. Regional Distribution - Upstream raw material suppliers are mainly located in Inner Mongolia, Guangdong, Fujian, and Beijing, while feed production companies are concentrated in Guangdong and Sichuan [6]. - The majority of downstream aquaculture companies are found in Guangdong, Jiangsu, and Henan provinces [6]. Company Developments - Major feed companies in China, such as New Hope, Haida Group, and Tongwei, have reported feed revenues exceeding 30 billion yuan, with some companies like Dabeinong and Jingji Zhino achieving gross margins above 11% [9]. - Haida Group and New Hope have high feed production and sales volumes, each exceeding 20 million tons [9]. - Investment activities in 2023 include establishing subsidiaries, new projects, and increasing capital in existing subsidiaries by leading feed companies [10].

证券代码：000876 证券简称：新希望 公告编号：2025-43 债券代码：127015,127049 债券简称：希望转债，希望转 2 关于召开 2024 年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1．本次股东大会为公司2024年年度股东大会。 2．会议的召集人为公司董事会，召开事项于2025年4月24日公司 第十届董事会第二次会议审议通过。 新希望六和股份有限公司 3．本次会议的召开合法、合规，符合有关法律、行政法规、部 门规章、规范性文件和公司《章程》的规定。 4．会议召开日期、时间 现场会议召开时间：2025年6月18日（星期三）下午14:00。 通过深圳证券交易所交易系统进行网络投票的时间为2025年6月 18日上午9:15—9:25、9:30—11:30，下午13:00—15:00。 通过互联网投票系统（http://wltp.cninfo.com.cn）投票的具体时间 为：2025年6月18日9:15-15:00。 5．会议召开方式：本次股东大会采用现场表决与网络投票相结 合的方式召开。 6．股 ...

证券代码：000876 证券简称：新希望 公告编号：2025-34 债券代码：127015,127049 债券简称：希望转债，希望转 2 新希望六和股份有限公司 第十届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司监事会认为董事会编制和审议的公司 2024 年年度报告的程 序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、 完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈 述或者重大遗漏。 本议案将提交公司 2024 年年度股东大会审议。 公司《2024 年年度报告全文》详见 2025 年 4 月 26 日巨潮资讯 网，《2024 年年度报告摘要》刊登于同日《中国证券报》《证券日报》 《证券时报》《上海证券报》和巨潮资讯网。 （二）审议通过了公司"2024 年度监事会工作报告" 表决结果：3 票赞成，0 票反对，0 票弃权。 一、监事会会议召开情况 新希望六和股份有限公司（以下简称"公司"）第十届监事会第 二次会议通知于 2025 年 4 月 14 日以电子邮件方式通知了全体监事。 第十届监事会第二次会议于 ...

新希望六和股份有限公司监事会 关于公司第十届监事会第二次会议相关事项的审核意见 一、关于公司《2024 年年度报告全文及摘要》的审核意见 公司监事会认为董事会编制和审议的公司 2024 年年度报告的程 序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、 完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈 述或者重大遗漏。 二、关于公司《2024 年度内部控制评价报告》的审核意见 监事（签名）： 徐志刚_________________ 段培林__________________ 庞允东__________________ 公司监事会及全体成员认真阅读了《2024 年度内部控制评价报 告》后认为：公司按照财政部、证监会等五部委联合发布的《企业内 部控制基本规范》和深圳证券交易所《上市公司自律监管指引第 1 号——主板上市公司规范运作》的要求，完成了《2024 年度内部控 制评价报告》的编制工作，公司内部控制符合深圳证券交易所《上市 公司自律监管指引第 1 号——主板上市公司规范运作》及有关法律、 法规、规范性文件的要求，真实、准确地反映了目前公司内部控制的 现状，公司内部控制评价报告中对公司 ...